Conference Call and Live Audio Webcast Scheduled for Wednesday, August 12, at 4:30 p.m. ET HOUSTON , Aug. 05, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc.  (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene expression, announced that the

New Patent Protects Composition of Matter and Methods of Use Through At Least August 2032 HOUSTON , Aug. 05, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced the

HOUSTON , Aug. 03, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. . (Nasdaq: SLRX) today announced the closing of its previously announced underwritten public offering of 5,130,390 shares of its common stock, including 669,181 shares sold pursuant to the exercise in full of the

HOUSTON , July 30, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced the pricing of an underwritten public offering of 4,461,209 shares of its common stock at a price to

HOUSTON , July 29, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced that it has commenced an underwritten public offering of shares of its common stock.

Pre-Clinical Data and Early Clinical Observations Support Company’s Decision to Research Seclidemstat as a Potential Treatment in Ewing-Related Sarcomas HOUSTON , July 29, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical stage oncology company targeting cancers

New Facilities Include Dedicated Laboratory Space for Preclinical Research HOUSTON , July 28, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced that it has relocated its

Veteran Biopharmaceutical Executive and Cancer Researcher Brings Extensive Clinical Development and Medical Affairs Experience to Salarius’ Seclidemstat Program HOUSTON , July 23, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company

Seclidemstat is currently being studied in a Phase 1/2 clinical trial for Ewing sarcoma, a rare and deadly pediatric bone cancer HOUSTON , June 02, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene

Patient Enrollment Continues in Phase 1/2 Dose Escalation Trial for Seclidemstat in Relapsed or Refractory Ewing Sarcoma HOUSTON , May 27, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by dysregulated gene